Can a spit test tell you you're in perimenopause?

The ad finds you at 2 a.m., because of course it does. Spit in a tube, mail it off, and a lab will tell you where you are in the transition. Your stage. Your numbers. Your personalized plan.

It's an appealing promise. A clear answer, delivered by post. But measuring a hormone and reliably identifying your stage of perimenopause are different questions.

And I understand the appeal. When symptoms are changing and you want answers, a number can feel reassuring. People seek care through different approaches, including naturopathy and traditional Chinese medicine. I respect those approaches and the practitioners who offer them. The question here is narrower: what can a particular test reliably tell you, and will that answer help you decide what to do next?

Why this promise finds an audience

You have blood work done. The results come back within the lab's reference ranges. But your sleep, periods or mood have changed, and you still want to understand why. It's easy to see why another test, especially one promising a more personal answer, might appeal.

A hormone result within the reference range doesn't, on its own, rule out perimenopause. Hormones fluctuate, and a sample captures one moment. That doesn't mean every symptom is hormonal or that normal blood work should be ignored. It means the result needs to sit alongside your symptoms, menstrual history and the question the test was ordered to answer. NICE's guidance explains why routine hormone testing usually isn't needed to identify perimenopause in otherwise healthy people aged 45 or over with the typical picture.

There's more investment attention on women's health, too, though the funding story isn't a straight upward line. SVB's 2026 report records $2 billion in venture investment across the U.S. and Europe in 2025, down from the 2024 peak. The World Economic Forum's 2026 investment outlook puts women's health at just 6% of private healthcare investment. That's a share of private investment, not a share of all health-research funding. It also reports that 90% of that limited investment goes to women's cancers, reproductive health and maternal health, with menopause among the underfunded areas.

The funding headline looks rather different from this end of midlife. A small side-eye feels reasonable. More investment attention doesn't, by itself, tell you whether the kit in your feed answers a useful question.

Then there's what happens to the information you leave behind while looking for answers. In its 2023 Premom case, the FTC alleged that the fertility app shared sensitive health data with Google and AppsFlyer without users' authorization; the settlement barred sharing personal health data for advertising. 1 That's a documented case involving a particular app, not evidence that every hormone-test company does the same thing.

Still, before ordering a kit or entering cycle dates, it's fair to ask: who gets my sample, who gets my results, and is any of this information used for advertising? Wanting an answer shouldn't mean having to guess what happens to the information you hand over.

What the guidelines say

If you're 45 or over, otherwise healthy, your periods are changing and you're waking up soaked, you usually don't need a hormone test to identify perimenopause. That's the usual approach in the guidelines, with room for assessment of your individual circumstances.

NICE and the British Menopause Society recommend a clinical diagnosis in otherwise healthy people aged 45 or over with the relevant symptoms and menstrual history. Age, menstrual history, symptoms. No routine confirmatory hormone test needed.

That doesn't mean ignoring other possible causes or never ordering blood work. It means a kit's stage label isn't what establishes the diagnosis.

What a snapshot can and can't tell you

Here's why timing matters. In perimenopause, estradiol doesn't decline in a neat slope. It can rise and fall erratically. Progesterone production changes as ovulation becomes less regular. FSH can fluctuate too. A single result needs context: when it was collected, symptoms, menstrual history and any hormones you're taking.

SWAN research found that average estradiol remained relatively stable until about two years before the final menstrual period, then declined. Another SWAN analysis identified four distinct estradiol trajectories, associated with factors including body size and race or ethnicity. Those population findings are real. They don't turn one sample into a reliable individual stage label.

A measured number can be accurate without settling the question you brought to it. It's worth asking how the result would change your care, and what its limits are.

Where were you in your cycle?

If a test measures reproductive hormones, the timing question belongs in the conversation: were you before ovulation, or in the luteal phase, the part of the cycle after ovulation? If you don't have predictable periods, or you're taking hormones, how will the person interpreting the result account for that? The collection date alone doesn't tell the whole story.

Progesterone is a useful example. In a fertility assessment, ASRM guidance recommends timing a blood progesterone sample about a week before the expected next period, rather than automatically on day 21. Even in the luteal phase, levels can fluctuate substantially over a few hours. A single result can support evidence of recent ovulation, but can't assess the quality of that phase.

That's guidance for a specific blood test used to assess ovulation. It isn't a collection schedule for a saliva kit, or a way to diagnose perimenopause. As cycles become less predictable during the transition, a fixed calendar day can be harder to interpret. Ask why that collection time was chosen for that test, what happens if you haven't ovulated or don't know your cycle phase, and what the result can actually establish.

Getting the timing right can help answer an appropriate testing question. It doesn't, on its own, validate a kit's promise to tell you your perimenopause stage.

Saliva, specifically

Saliva testing has been used alongside compounded "bioidentical" hormones to guide dosing. The guidance below addresses that specific use, rather than every possible use of saliva testing.

The Menopause Society's 2022 hormone therapy position statement calls using serum, salivary, or urine testing to guide compounded hormone dosing "unreliable," citing pharmacokinetics, diurnal variation, and variability between and within individuals. Its key points say salivary and urine hormone testing to determine dosing are unreliable and not recommended; serum hormone testing is rarely needed. A decade earlier it called saliva testing for compounded hormones "inaccurate and unreliable."

The FDA says there's no scientific basis for using saliva testing to adjust hormone levels. The Endocrine Society describes a lack of standardization and evidence supporting serial saliva testing to dose compounded hormones. The bodies cited here agree on that use: it isn't a sound basis for personalized hormone dosing.

The dried-urine version

The DUTCH test is the newer, more expensive entry: dried urine samples collected across the day to measure hormones and metabolites; pricing varies by panel and practitioner. The company has published papers showing its measurements line up analytically with blood and liquid urine. That's real, and worth saying plainly.

But analytical agreement isn't clinical usefulness. Those validation papers, written by researchers affiliated with the manufacturer, don't establish that using the panel to stage perimenopause or guide treatment improves outcomes. I found no independent outcome evidence for those uses. The Menopause Society doesn't recommend urine hormone testing to determine hormone doses.

Those findings support the measurement method. They don't, on their own, establish that the panel reliably identifies perimenopause stage or improves treatment outcomes. That distinction matters without writing off the whole test or the person using it.

I know naturopaths I respect who use this test. A discussion of results within an ongoing care relationship is different from a kit promising a stage label by post. That relationship matters, but it doesn't remove the need to explain what a test has and hasn't been shown to do. I want that clarity from every approach to care.

The market

The shelf is crowded now. Mira, Everlywell, LetsGetChecked and Hormona sell hormone-testing products; formats, prices and claims vary. A device measuring hormones isn't the same thing as an independently validated perimenopause staging method. Drugstore urine FSH sticks are another version of the snapshot.

You'll see "CLIA-certified lab" on many of these. CLIA concerns laboratory quality standards. It isn't an endorsement of a kit's clinical staging claim. A well-run lab can precisely measure a hormone without that number answering the question on the box.

What regulation does and doesn't establish

This isn't the first time. In 2005, the FTC sent warning letters to 34 websites and the FDA to 16 more over "natural alternative HRT" products. In 2007, the FTC charged seven sellers. In 2008, the FDA warned seven compounding pharmacies over "bioidentical" hormone claims. Those actions concerned specific product claims. They don't establish that today's test brands, or a whole profession, made the same claims.

U.S. laboratory-developed tests sit in a changing regulatory landscape. The FDA's May 2024 rule was vacated by a federal court in March 2025; in September 2025, the agency reverted the regulation to its earlier text. That doesn't establish that every home kit is a laboratory-developed test, or that any particular test's clinical claims are validated.

I didn't find current enforcement actions against the test brands discussed here. Enforcement history alone doesn't tell us whether a particular clinical use is supported.

What testing is actually for

None of this means never test. It means test when the result changes the decision.

NICE says to consider serum FSH in people aged 40 to 45 with menopause-associated symptoms and a change in their menstrual cycle, and in those under 40 when menopause is suspected. Suspected premature ovarian insufficiency needs its own assessment, not a home-kit verdict.

Other tests can be appropriate for other questions: thyroid testing when thyroid disease could explain the picture, a pregnancy test when it could be that, a blood count when bleeding is heavy. These are decisions to make with a doctor or specialist, not a universal testing checklist.

NICE says not to use FSH to identify menopause while taking combined oestrogen and progestogen contraception or high-dose progestogen. Not every contraceptive method makes FSH uninterpretable.

For someone over 45 with typical symptoms, a routine stage-confirmation kit usually isn't needed. If the picture is less clear, discuss what assessment or testing would help.

One useful option, alongside care, is tracking symptoms, sleep and bleeding over weeks. It can help you see what happened, when, and how it affected you, for yourself or a conversation with a doctor or specialist. It doesn't diagnose perimenopause or replace appropriate testing.

What I'd ask is simple: what question is this test answering, what evidence supports that use, and what would we do differently with the result? That's a fair conversation with any practitioner.

---

Sources: World Economic Forum, Women's Health Investment Outlook 2026; SVB, Innovation in Women's Health 2026; ASRM fertility evaluation committee opinion, 2021, cited for blood progesterone timing in fertility assessment, not perimenopause diagnosis; FTC Premom case, 2023; The Menopause Society 2022 Hormone Therapy Position Statement; The Menopause Society 2012 statement; U.S. Food and Drug Administration on menopause and saliva testing; Endocrine Society, Santoro et al., 2016; NICE Guideline NG23; British Menopause Society, January 2026; SWAN hormone trajectories, 2012 and SWAN review, 2019; BMC Chemistry 2019 analytical validation and 2021 validation, both involving manufacturer-affiliated authors; FTC/FDA warnings, 2005, FTC charges, 2007; FDA laboratory-developed test rule and its vacatur.

Piece 4 of 6 · Test only when the result changes the decision. · Framework: Human-centred evidence

Companion pieces: Your ring doesn't know how last night felt · The patient at the centre of the record doesn't exist